Erica DiNapoli

Erica DiNapoli is an Assistant Editor for OncLive®. She joined the company in 2020 and now assists in editing and publishing both videos and informational articles to the website; she also helps manage the social media platforms. Prior to joining MJH Life Sciences, she was a student at Monmouth University and held two marketing internships at United Teletech Financial Federal Credit Union and Trendsetter Media & Marketing.

Articles

Despite Efforts Made With Immunotherapy in Metastatic Urothelial Cancer, Chemotherapy Remains King in Frontline

December 30th 2020

Shilpa Gupta, MD, discusses ongoing research with immunotherapy in bladder cancer, where research efforts should focus with regard to biomarkers, and other emerging agents that might move the needle forward.

Petrylak Shares Selection Considerations for Available Agents in Hormone-Sensitive Prostate Cancer

December 29th 2020

Daniel P. Petrylak, MD, highlights the use of abiraterone acetate, enzalutamide, and apalutamide and how these agents can lead to improvements in overall survival and progression-free survival in patients with hormone-sensitive prostate cancer.

Immunotherapy Combos Take Next Step in Gynecologic Cancers

December 29th 2020

R. Wendel Naumann, MD, discusses numerous investigations of PD-1 inhibitors in combination with PARP inhibitors or other targeted agents, as well as chemotherapy, and how it could finally start the next chapter of immunotherapy in gynecologic malignancies.

Antiandrogens Plus ADT Continue to Reign Supreme in Nonmetastatic CRPC

December 28th 2020

Michael E. Hurwitz, MD, PhD, highlights the role of second-generation androgen blockers in nonmetastatic castration-resistant prostate cancer, how these agents compare, and active areas of investigation.

Janku Highlights PFS Benefit With Dose-Escalated Ripretinib in Advanced GIST

December 15th 2020

Filip Janku, MD, PhD highlighted a dose-escalated approach of ripretinib and how it yielded a progression-free survival benefit in patients with gastrointestinal stromal tumor across all lines of treatment in a phase 1 study.

TNBC Treatment Paradigm Advances With the Rise of Chemoimmunotherapy Combos

December 15th 2020

Neelima Vidula, MD, highlights some of the pivotal trials evaluating immunotherapy combination regimens in triple-negative breast cancer, some of the challenges faced in practice, and areas for further exploration.

Sznol Advocates for More Awareness of Immune-Related Toxicities

December 14th 2020

Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.

Expert Expands on Recent Advances With Actionable Alterations Spanning GI Cancers

December 7th 2020

Nathan Bahary, MD, PhD, discusses the importance of seeking targetable alterations in GI cancers, as well as recent advancements in the space.

MCL Treatment Shifts Away from Chemoimmunotherapy, Enters New Era of Novel Agents and Cellular Therapies

December 4th 2020

With the shift away from chemoimmunotherapy, and the adoption of novel combinations, as well as cellular therapy, the MCL treatment landscape has entered a new era. Looking forward, minimal residual disease is bound to play a critical role in terms of guiding treatment selection.

Understanding Biomarker Differences Becomes Critical as Precision Medicine Rises in Melanoma

December 4th 2020

Jason J. Luke, MD, FACP discusses the role of precision medicine and how it continues to lead the way in all areas of oncology, but especially in melanoma.

Need for Genetic Testing Becomes More Pronounced in Breast, Gynecologic Cancers as Targeted Approaches Abound

December 2nd 2020

Lan G. Coffman, MD, PhD, discusses the role of genetic testing in breast and gynecologic cancers and the many advances made with targeted therapies.

Chemoimmunotherapy Transforms the Lung Cancer Armamentarium

December 2nd 2020

Vignesh Narayanan, MD, the role of chemoimmunotherapy and how it has truly changed the game in the treatment of patients with lung cancer.

Nanoliposomal Irinotecan Could Play a Role in Pancreatic Cancer, But Questions Remain

December 2nd 2020

Jordan D. Berlin, MD, discusses the unmet needs in pancreatic cancer treatment and ongoing research efforts with nanoliposomal irinotecan.

Pancreatic Cancer Trial Platform Poised to Lead to Quicker, More Efficient Research

November 30th 2020

Vincent J. Picozzi Jr, MD, spotlights the launch of PanCAN’s Precision Promise clinical trial platform, and how it is expected to impact clinical practice.

Immunotherapy Leads the Way in Lung Cancer, but Creates Complex Treatment Decisions

November 27th 2020

Joshua Reuss, MD, discusses the lung cancer armamentarium, the role of immunotherapy combinations, and the significance of biomarkers.

CAR T-Cell Therapy Transforms Leukemia and Lymphoma Treatment, But Toxicity Concerns Remain

November 24th 2020

Olalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.

Usmani Highlights Impact of Latest Daratumumab Triplet Approval in Lenalidomide-Refractory Myeloma

November 19th 2020

Saad Z. Usmani, MD, FACP, discusses the significance of the FDA approval of daratumumab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma who have received at least 1 previous line of therapy.

BTK Inhibitor Combos Could Transform the Complex CLL Armamentarium

November 18th 2020

Alan P. Z. Skarbnik, MD, breaks down factors that should be kept in mind when navigating the complex chronic lymphocytic leukemia armamentarium as it relates to BTK inhibitors.

Novel Mechanism of Action and Tolerability Makes Telaglenastat a Promising Player in RCC

November 17th 2020

Chung-Han Lee, MD, PhD, discusses the promise of telaglenastat in renal cell carcinoma and the research efforts examining the agent in different combinations.

CRC Treatment Enters New Era Where Personalized Care Is King

November 16th 2020

Nilofer S. Azad, MD, highlights colorectal cancer treatment and how it has entered an era that is both exciting and challenging.